Here are six updates on GI companies from the past week:
SGS United Kingdom withdrew GI Dynamics' CE Mark for its EndoBarrier device.
IQuility is releasing IsolateIBS-IBD, a RNA-based blood test that can help physicians identify irritable bowel syndrome or inflammatory bowel disease.
After discontinuing a drug therapy program that "did not live up to its promise," Outpost Medicine shifted its focus towards OP-687, an oral therapy for overactive bladder and irritable bowel syndrome.
After announcing positive results from its second phase III trial, Global Data Healthcare Analysts' Maria Sudul said Ardelyx's Tenapanor is in line to make a "successful market entry."
Lumendi completed the first in-human trials of its DiLumen Endolumenal Interventional Platform technology, meeting the study's primary endpoint.
The U.S. Patent and Trademarks Office granted Immuron a patent for its non-alcoholic steatohepatitis treatment.